Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,528,000
+14,000 (0.92%)
At close: Apr 24, 2026
Samsung Biologics Revenue
Samsung Biologics had revenue of 1.26T KRW in the quarter ending March 31, 2026, a decrease of -3.18%. This brings the company's revenue in the last twelve months to 4.81T, down -1.73% year-over-year. In the year 2025, Samsung Biologics had annual revenue of 4.56T with 30.31% growth.
Revenue (ttm)
4.81T
Revenue Growth
-1.73%
P/S Ratio
14.69
Revenue / Employee
926.66M
Employees
4,770
Market Cap
70.73T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.56T | 1.06T | 30.31% |
| Dec 31, 2024 | 3.50T | -197.44B | -5.34% |
| Dec 31, 2023 | 3.69T | 693.29B | 23.10% |
| Dec 31, 2022 | 3.00T | 1.43T | 91.41% |
| Dec 31, 2021 | 1.57T | 403.23B | 34.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celltrion | 4.16T |
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 706.74B |
| SK bioscience | 651.37B |
| ALTEOGEN | 215.86B |
| LigaChem Biosciences | 141.55B |
| HLB Co., Ltd. | 84.17B |
| OliX Pharmaceuticals | 14.67B |
Samsung Biologics News
- 3 days ago - Samsung BioLogics Co Ltd (XKRX:207940) Q1 2026 Earnings Report Preview: What To Expect - GuruFocus
- 6 weeks ago - Rapid Micro Biosystems (RPID) Expands Partnership with Samsung Biologics - GuruFocus
- 6 weeks ago - Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance - Benzinga
- 6 weeks ago - Samsung Biologics Teams Up With Eli Lilly To Establish Lilly Gateway Labs Site In Korea - Nasdaq
- 3 months ago - Samsung BioLogics Co Ltd (XKRX:207940) Q4 2026 Earnings Report Preview: What To Look For - GuruFocus
- 4 months ago - Samsung Biologics Expands U.S. Presence with $280M Acquisition - GuruFocus
- 4 months ago - Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln - Nasdaq
- 4 months ago - Samsung Biologics to Acquire Human Genome Sciences from GSK - GuruFocus